Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Bob Moriarty | It’s Time to Buy Silver!

In this interview, Bob Moriarty of 321gold sits down with Maurice Jackson of Proven and Probable to discuss a number of important topics ranging from hospital cost incentives regarding the COVID-19, and the how the economy...
Maurice Jackson | May 19, 2020 |

Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho

Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. Assembly Biosciences Inc (ASMB:NASDAQ) announced in a press release on October 16, 2019, ...
Streetwise Reports | October 17, 2019 |

Viela Bio Shares Trade Higher After Analyst Issues 'Buy' Recommendation

Shares of Viela Bio Inc. rose 20% after an analyst at H.C. Wainwright & Co. initiated coverage of the stock. This morning, shares of clinical-stage biotechnology firm Viela Bio Inc. (VIE:NASDAQ) , which is focused on pioneering treatments for autoimmune and...
Streetwise Reports | February 19, 2020 |

Texas Firm Represents 'Inexpensive Way to Buy Integration in Midstream'

The reasons this energy firm warrants a rerating are discussed in a Raymond James report. In an Aug. 28 research note, analyst J.R. Weston reported that Raymond James upgraded Targa Resources Corp. (TRGP:NYSE) to Strong Buy from Outperform "as we feel this is an att...
Streetwise Reports | September 9, 2019 |

Oil & Gas Services Company Upgraded to Buy

The reasons behind the changed rating and expectations for the firm's Q4/19 are presented in an iA Securities report. In a Jan. 27 research note, analyst Elias Foscolos reported that iA Securities upgraded its rating on Pason Systems Inc. (PSI:TSX) to Buy ...
Streetwise Reports | January 31, 2020 |

Oil & Gas Company Increases Credit Term Facility to Fund Second Well

The terms and the reason are presented in a Mackie Research Capital Corp. report. In a Nov. 1 research note, Mackie Research Capital Corp. analyst Bill Newman reported that Touchstone Exploration Inc. (TXP:TSX; PBEGF:OTC.MKTS) increased its term credit facility to $...
Streetwise Reports | November 14, 2019 |

STACK Agreement 'Positive' for Area Operator

The deal details are relayed in a ROTH Capital Partners report. In a Dec. 10 research note, ROTH Capital Partners analyst John White purported that a recent development in the industry is positive for Chaparral Energy Inc. (CHAP:NYSE) as its primary areas of operati...
Streetwise Reports | December 13, 2019 |

After Biotech Dives Deeper Into Melanoma Data, It 'Continues to Impress'

Details from this clinical program are discussed, along with Q2/19 earnings and the next stock catalyst, in an H.C. Wainwright & Co. report. In an Aug. 23 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported the highlights from Targovax ASA's (TRVX:...
Streetwise Reports | August 28, 2019 |

FDA Approves First-of-Its-Kind, Adult Pneumonia Antibiotic; September Launch Planned

The drug's features and its developer's commercial plans are discussed in an H.C. Wainwright & Co. report. In an Aug. 20 research note, analyst Ed Arce reported that H.C. Wainwright & Co. raised its target price on Nabriva Therapeutics Plc (NBRV:NASDAQ) to $8 per sh...
Streetwise Reports | August 28, 2019 |

Two Analysts See Company as a Buy for 'Game-Changing' Potential in Bladder Cancer ...

Two Analysts See Company as a Buy for 'Game-Changing' Potential in Bladder Cancer Detection and Surgery The disruptive technology is 'poised to deliver significant advancement in bladder cancer detection.' Imagin Medical Inc. (IME:CSE; ...
Streetwise Reports | January 15, 2020 |
1 2 3 4 5 6 7 8 9 10 ...